BRIEF-Novo Nordisk Says U.S. FDA Has Approved Wegovy™ For Chronic Weight Management

by Reuters
Friday, 4 June 2021 18:14 GMT

June 4 (Reuters) - Novo Nordisk A/S:

* US FDA HAS APPROVED WEGOVY™ ( BRAND NAME FOR ONCE-WEEKLY SEMAGLUTIDE 2.4 MG INJECTION IN US) FOR CHRONIC WEIGHT MANAGEMENT

* EXPECTS TO LAUNCH WEGOVY(TM) IN UNITED STATES LATER IN JUNE 2021

* APPROVAL IS BASED ON RESULTS FROM STEP PHASE 3A CLINICAL TRIAL PROGRAMME Source text for Eikon: Further company coverage:

Our Standards: The Thomson Reuters Trust Principles.